UNSPSC 51332902: Nicergoline

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C24H26BrN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JCV8365FWN, chemically known as 10-methoxy-1,6-dimethylergoline-8.beta.-methanol 5-bromonicotinate ester but generally known as nicergoline, which bears US NIH Compound Identifier 4475. European Medicines Agency schedules Nicergoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09226MIG.

UNSPSC 51332902 Nicergoline is a Commodity code for a specific pharmaceutical ingredient, yet recent state and local opportunities tagged under it diverge significantly from this narrow product scope. The most recent solicitations instead cover broad pharmaceutical procurement categories—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products—suggesting either tagging misalignment in the source data or that nicergoline sits within a broader pharmaceutical-supply procurement context. The issuing bodies are diverse state and local entities: Seminole County, Florida (a county government); the Texas Health and Human Services Commission (a state agency); and the Minnesota Multistate Cooperative Purchasing Alliance (a multi-state cooperative purchasing vehicle administered by the Minnesota Department of Administration). The actual work being solicited spans product procurement (naloxone units and safe drug deactivation systems), market intelligence gathering on direct pharmacy contracting models, and establishment of statewide or multi-state pharmaceutical supply contracts with pricing and distribution through authorized wholesalers.

The geographic spread includes Florida, Texas, Minnesota, and Oregon, reflecting activity across multiple regions rather than concentration in a single jurisdiction. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023—note the date discrepancy in source records) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The code shows limited relevant recent activity aligned with its nominal nicergoline scope; the opportunities reflect broader pharmaceutical supply and procurement strategy rather than a single active ingredient market.